BCL2L1 and mantle cell lymphoma: To increase the efficacy of venetoclax therapy in MCL, combining venetoclax with inhibitors targeting the other anti-apoptotic BCL-2 proteins MCL-1 and BCL-XL would be an excellent strategy.